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10.00 – 10.55  Registration / Tea and Coffee.
10.55 – 11.00 Welcome.
11.00 – 12.15 Oral Presentations. Plenary I: clinical research.
12.15 – 13.15 Keynote address: “The 100,000 Genomes 
Project” Prof. Mark Caulfield, William Harvey    
Research Institute, Bart’s and The London 
School of Medicine and Dentistry, Queen Mary 
University of London, UK.
13.15 – 14.15 Lunch (Provided) and Poster viewing.
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14.15 – 15.30 Oral presentations. Plenary II: Basic research.
15.30 – 16.00 Tea and coffee / Poster viewing.
16.00 – 16.15 ISHG AGM.
16.15 – 17.15 Keynote address: “Clinical Implications of 
2-day whole genome sequencing of acutely ill 
infants” Prof. Stephen Kingsmore, Dee Lyons/
Missouri Endowed Chair in Genomic Medicine, 
Children’s Mercy - Kansas City, USA.
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SPOKEN PAPERS:
S01. Diagnostic Yield of the Microarray in Paediatric Practice
HA Deeny1, AM Murphy1, D O’Rourke2, S Gallagher1
1Paediatrics Department, University Hospital Limerick, 
2Department of Laboratory Medicine, University Hospital Limerick
Comparative Genomic Hybridisation (CGH) Microarray has 
been available in Ireland to Paediatricians from the year 2011. 
Guidelines for investigation of infants and children with features 
of developmental delay, dysmorphic features and some cases of 
epilepsy, recommend the use of CGH Microarray as part of a series 
of investigations1.
Our study focused on infants and children screened over the 36 
month period from July 2011 to July 2014. Any parent samples 
sent were excluded and data was entered anonymously on to an 
excel spreadsheet. Data extracted included; Patient demographics, 
requesting speciality and indications for testing (Global 
Developmental delay (GDD), Autism (ASD), Dysmorphic features, 
Epilepsy and other).
The results showed n=303 children and infants had a microarray 
sent during the 36 month period chosen. Of these 248 were 
available for processing. Indications were 46% for Developmental 
delay, 22.5% for ASD, 14% for dysmorphic features and 12% 
epilepsy. 23% overall were returned with abnormal Microarray 
with 14.5% BCNV. Diagnostic yield was 7.3% overall with a 
9.5% yield in GDD and 10.9% in ASD. This correlates with 
previous studies showing a diagnostic yield of 7.8% in GDD and 
10.6% in dysmorphic children2. In conclusion the Microarray is an 
investigation in limited selection of disorders and can aid clinicians 
in obtaining a diagnosis in previously extensively investigated 
children with no definitive diagnosis.
References: 1. Miller DT et al. Consensus statement: Chromosomal Microarray Is a 
First-Tier Clinical Diagnostic Test for Individuals with Developmental Disabilities or 
Congenital Anomalies. Am J Hum Genet. 2010;86(5):749. 2. Ellison JW et al. Clinical 
Utility of Chromosomal Microarray Analysis. Pediatrics 2012;130(5):e1085-95.
S02. The Next Step in Cardiac Genetics: Targeted gene panels 
and next generation sequencing in inherited cardiac conditions
G Rea1,2, JS Ware1,2, EG Lightman2, R Walsh1,2,  S John2  ,T 
Homfray3, J Till3, S Prasad3, R Buchan2, S Wilkinson2, PJR 
Barton1,2, SA Cook1,2,4
1National Heart and Lung Institute, Imperial College, London SW3 
6LY, UK 2NIHR Cardiovascular Biomedical Research Unit, Royal 
Brompton and Harefield NHS Foundation Trust, London SW3 
6NP, UK 3Royal Brompton and Harefield NHS Foundation Trust, 
London SW3 6NP, UK 4Department of Cardiology, National Heart 
Centre Singapore, Singapore 168752, Singapore
Inherited cardiac conditions (ICCs) represent a significant cause 
of morbidity and mortality. Wide variability in expression and 
penetrance limit the utility of clinical cascade screening in families, 
whilst the role of molecular diagnosis has traditionally been 
hampered by the genetic heterogeneity of many ICCs. Currently, 
new genomic sequencing technologies are transforming the role 
of molecular genetic testing in ICCs, substantially increasing the 
diagnostic yield, allowing accurate diagnosis, risk stratification, 
targeted therapy and cascade molecular screening.  We report 
selected cases from our experience with targeted gene panels 
coupled with next generation sequencing (NGS) in families 
with suspected ICC’s. Advantages of NGS include the ability to 
comprehensively sequence large genes such as TTN and RyR2 and 
the ability to simultaneously sequence multiple genes implicated 
in disease, including genes for phenocopies, reducing the need to 
multiple stage testing.  We illustrate the impact that targeted gene 
panels coupled with NGS are having on patient care with respect 
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to ICCs, using illustrative cases of Dilated Cardiomyopathy, 
Catecholaminergic Polymorphic Ventricular Tachycardia and 
Sudden Unexplained Death. The molecular aetiology in these cases 
would not have been identified using conventional approaches. By 
demonstrating the transformative potential of this approach we 
seek to motivate clinicians to move to comprehensive gene panels 
as a first line for genetic testing in ICCs, to ‘re - test’ previously 
‘genotype negative’ ICC samples and to consider broad based 
molecular genetic testing in selected novel situations.
S03. An overview of the incidence and impact of MYH polyposis 
gene mutations in an Irish Cohort
TP McVeigh1, N Cody1, M Meany1, C Carroll1, R O’Shea2, DJ 
Gallagher2, C Clabby1, AJ Green1
1Department of Clinical Genetics, Our Lady’s Children’s Hospital 
Crumlin, 2Mater Misericordiae University Hospital
The MYH gene encodes a DNA-glycosylase enzyme, which is 
involved in base excision repair. Bi-allelic mutation of MYH confers 
predisposition to polyposis and gastro-intestinal malignancies, and 
is distinct genetically and clinically from autosomal dominant 
adenomatous polyposis coli. In Europe, two common mutations 
(G382D and Y175C) are reported in 90% of MYH-associated 
polyposis. We aimed to examine the incidence and impact of MYH 
mutations in an Irish cohort. A retrospective cohort study was 
undertaken. Patients tested for MYH mutations were identified by 
searching electronic patient databases iGene and Crumbase using 
terms “MUTYH” and “MYH”.  Patient charts were reviewed for 
details regarding phenotype and genotype.
Ninety-four patients from forty-one families were tested for 
MYH mutations. Bi-allelic mutations were identified in eighteen 
individuals (14 families), and mono-allelic mutations in another 
28. At least one of G382D or Y175C was detected in bi-allelic 
cases. Nine families had bi-allelic status for one/both common 
European mutations. There was no age difference between mono- 
and bi-allelic mutation carriers (51±16–v-56±13years, p=0.244). 
Nine (50%) bi-allelic mutation carriers developed cancer of colon/
rectum, compared to 1(4%) patient with mono-allelic mutation. 
The average age at diagnosis was 49 years (±13). Polyposis was 
reported in eleven (61%) bi-allelic and 3(11%) mono-allelic 
mutation carriers.
Mutations were detected in 14/41(34%) families. Bi-allelic MYH 
mutations confer a strong risk of early-onset colorectal cancer, while 
risk in mono-allelic carriers reflects that of background population. 
Screening of bi-allelic mutation carriers is recommended, while 
screening mono-allelic carriers may not be of any extra benefit over 
routine national screening programs.
S04. When it comes to exomes, expect the unexpected
J Casey1, E Crushell2, J Hughes2, E Losty2, D Slattery3, A Green4, S 
Ennis5, SA Lynch1
1Genetics Department, Temple Street Children’s University 
Hospital, 2National Centre for Inherited Metabolic Disorders, 
Temple Street Children’s University Hospital, 3Respiratory 
Department, Temple Street Children’s University Hospital, 4Our 
Lady’s Children’s Hospital Crumlin, 5UCD Academic Centre on 
Rare Diseases.
Consanguinity, or cousin marriage, is widely practised in several 
global communities. It is well known that consanguinity increases 
the risk of having a child with an autosomal recessive disorder. Our 
exome sequencing studies involving consanguineous Irish Traveller 
families have led to some additional unexpected findings.
Firstly, we found that the risk of incidental findings in 
consanguineous families is skewed; there is a reduced risk of 
identifying dominant disorders and carrier status but an increased 
risk of identifying additional recessive disorders. On average, we 
analyse <1% of the total exome variants after implementing filtering 
criteria which should minimise/eliminate the risk of incidental 
findings. Nevertheless, we have made an incidental finding in 10% 
of families which is much higher than the expected 3% in non-
consanguineous families.
Secondly, we found that 26% of patients who underwent exome 
sequencing had more than one recessive disorder. In some cases, 
a second recessive disorder was suspected prior to sequencing. In 
others, it was unexpected. The presence of two recessive disorders 
results in unusual phenotypes which complicates making a diagnosis. 
In most cases, the mutations causing the two recessive disorders 
are on different chromosomes. However, in some families, the 
causative mutations are in linkage disequilibrium and co-segregate. 
It is important to determine whether the two disorders are linked or 
not as it has important implications for genetic counselling.
In conclusion, our exome studies have raised the interesting 
observation of patients having multiple recessive disorders, 
highlighting the need for careful clinical workup and data analysis.
S05. Translating research exome analysis into clinical practice 
– the Belfast-DDD experience
CW Kirk, S McKee, DDD Project
Northern Ireland Regional Genetics Service
Rare genetic syndromes causing dysmorphism and disability in 
childhood pose a significant diagnostic challenge, and traditional 
“one gene at a time” methods result in a diagnostic odyssey that 
can be time consuming and expensive. The DDD (“Deciphering 
Developmental Disorders”) Study has recruited almost 14,000 
cases of rare, presumably genetic, disorders into a pipeline to 
deliver full exome data as well as copy number analysis, in an 
effort to identify new disease genes and advance the use of next 
generation sequencing in diagnostics.
Since the project started in 2012, the NI Regional Genetics Service 
has recruited over 700 families, making it the second-highest 
recruiter per capita in the UK. We have received results in 34 cases 
so far, and analysis is on-going in the others.
Among the genes identified are: ANKRD11, PPP2R1A, PPP2R5D, 
SATB2, SYNGAP1 and GRIN2B. Many of these diagnoses were 
unexpected, or the genes unavailable for testing via the routine 
clinical service.
Feedback from the families has been universally positive, allowing 
several families to achieve “closure” in relation to the diagnosis 
in a deceased child, or to appreciate recurrence risks for future 
pregnancies.
Challenges remain in moving this research pathway into the routine 
clinical arena, and larger studies such as the UK 100,000 Genomes 
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Project demonstrate that each new advance is a stepping stone on a 
long road. We require robust analyses of the clinical and financial 
benefits of these new technologies, and a clear commitment from 
health service providers that this is the direction we should be 
taking.
S06. NRXN1 (Neurexin-1) deletion; A common finding with 
advent of array but what are its effects?
M Al Shehhi1, S Shen2, L Gallagher3, DR Betts1, L McArdle1, A 
Green1, SA Lynch1
1Department of Clinical Genetics, OLCHC, Dublin, 2Regenerative 
Medicine Institute, School of Medicine, National University of 
Ireland (NUI) Galway, 3Trinity Centre for Health Sciences, St. 
James’s Hospital, Dublin
Recently both point mutations and deletions of neurexin-1 
(NRXN1) have been described as a common cause of Autism 
spectrum disorder (ASD) and other neurodevelopmental disorders. 
We have identified 37 individuals with NRXN1 deletions in our 
database of which 22 were index cases. We sought to ascertain the 
presenting features of index cases and the phenotype, if any, in their 
relatives.
The cohort was identified by database review of patients referred 
to our department in whom a neurexin-1 deletion was identified. 
Chromosome array testing was performed at the cytogenetics 
laboratory at OLCHC and Guys Hospital London. Genomic data 
and clinical phenotype information was extracted and analysed.
18/22 (82%) probands were investigated because of developmental 
delay particularly in speech and language. 4/22 (64%) patients had 
ASD, 13 had learning difficulties, 4 had seizures. Interestingly, 6/22 
were tested because of malformation including congenital heart 
defect. 8/22 had intronic deletions. 3/22 cases arose de novo.  Of 
the 15 inherited deletions, 2 relatives had a mild ASD phenotype. 
The majority 13/15 of relatives identified as deletion carriers had a 
normal phenotype.
Our data suggest that neurexin-1 deletions present with a variable 
phenotype and are not fully penetrant. Whilst, a parent that carries 
the deletion has a 50% risk of passing the deletion on, the risk 
of a child developing ASD is unknown. Genetic Counselling is 
problematic as the additional factors that trigger the phenotype are 
unclear. Cascade screening is currently not recommended as it is 
not possible to predict development of ASD accurately. Intron 5 
deletion is pathogenic and further genotype-phenotype correlation 
studies may help us understand the variability observed.
S07.  Transcriptome analysis of CD4+ T cells in coeliac disease
EM Quinn*, C Coleman*, B Molloy, P Dominguez Castro, V 
Trimble, N Mahmud, R McManus
Department of Clinical Medicine, Trinity College Dublin, St James 
Hospital, Dublin 8.
Genetic studies have to date identified 43 genome wide significant 
coeliac disease susceptibility (CD) loci comprising over 70 
candidate genes. However, how altered regulation of such disease 
associated genes contributes to CD pathogenesis remains to be 
elucidated. Recently there has been considerable emphasis on 
characterizing cell type specific and stimulus dependent genetic 
variants. Therefore in this study we used RNA sequencing to 
profile over 70 transcriptomes of CD4+ T cells, a cell type crucial 
for CD pathogenesis, in both stimulated and resting samples 
from individuals with CD and unaffected controls. We identified 
extensive transcriptional changes across all conditions, with 
the previously established CD gene IFNy the most strongly up-
regulated gene (log2 fold change 4.6; P
adjusted 
= 2.40x10-11) in 
CD4+ T cells from CD patients compared to controls. We show 
a significant correlation of differentially expressed genes with 
genetic studies of the disease to date (P
adjusted 
= 0.002), and 21 CD 
candidate susceptibility genes are differentially expressed under 
one or more of the conditions used in this study. Pathway analysis 
revealed significant enrichment of immune related processes. 
Co-expression network analysis identified several modules of 
coordinately expressed CD genes. Two modules were particularly 
highly enriched for differentially expressed genes (P<2.2x10-16) and 
highlighted IFNy and other genetically associated transcription 
factors which showed significantly reduced expression in coeliac 
samples as key regulatory genes in CD.
S08.  Oestrogen withdrawal, breast cell transformation, and 
breast cancer risk in women with the KRAS-variant
TP McVeigh1, S Jung2, D Salzman3, MJ Kerin1, S Nallur3, M 
Dookwah3, AA Nemec3, J Sadofsky3, T Paranjape3, O Kelly3, 
E. Chan3, N Miller1, KJ Sweeney1, D Zelterman3, J Sweasy3, R 
Pilarski4, D Telesca2, JB Weidhaas2
1National University of Ireland Galway, Galway, Ireland 2University 
of California, Los Angeles, Los Angeles, CA, United States 3Yale 
University, New Haven, CT, United States  4Ohio State University 
Wexner Medical Center, James Cancer Hospital, Columbus, OH, 
United States
The KRAS-variant rs61764370 is a single nucleotide change in 
the let7a-binding site of the KRAS gene. It has been previously 
associated with increased risk of cancer of the breast and ovary. 
This risk may be modified by environmental factors such as HRT 
use.
We aimed to evaluate the effect of oestrogen exposure and 
withdrawal on development of breast cancer in patients with the 
KRAS-variant.
Isogenic mammary (MCF10A) cell lines with and without KRAS-
variant were cultured and observed for oncogenic transformation 
in charcoal-stripped media following withdrawal and restoration 
of oestrogen. In vivo investigation was performed by case-
control analysis. Data was collected with respect to pathological 
characteristics, reproductive risk factors and anthropomorphic 
measurements from a cohort of patients with breast cancer and an 
unaffected control group of variant carriers.
Addition of tamoxifen to charcoal-stripped media led to 7.9-fold 
increase in oncogenic transformation in isogenic cell lines with the 
KRAS-variant, with reduction in colony formation after restitution 
of oestrogen. In vivo, affected carriers were significantly more 
likely to have had an oophorectomy pre-diagnosis than wild-type 
patients (p=0.033), and had lower median BMI (p<0.01) than 
unaffected participants with the variant . HRT-discontinuation in 
variant carriers was significantly associated with post-menopausal 
triple negative breast cancer (p<0.0001), and with cancer of higher 
grade (p<0.0001).
Oestrogen withdrawal in vitro and a low oestrogen state in vivo 
appear to increase risk of breast cancer and predict aggressive 
tumour biology in women with the KRAS-variant.
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S09.  Identifying genetic predictors of skin cancer in renal 
transplant populations
CP Stapleton1, M McCormack1, D Connaughton2, PJ Phelan3, GL 
Cavalleri1, PJ Conlon2
1Department of Molecular and Cellular Therapeutics, RCSI, 
Dublin, 2Beaumont Hospital Kidney Centre, Dublin, 3Department 
of Nephrology, Royal Infirmary of Edinburgh, NHS Lothian.
Renal-transplant recipients have a 33-fold increased risk of 
developing non-melanoma skin cancer relative to an age-matched 
non-transplanted individual. In this study we set out to map germline 
genetic variations influencing the development of skin cancer in 
our cohort of 325 renal-transplant recipients, using a genome-wide 
association study (GWAS) and candidate gene study design.
Both logistic regression and survival analysis was applied in our 
GWAS. Survival analysis was used in our candidate gene study. 
Multiple robust genetic loci for skin cancer in non-transplant 
populations have been identified via large GWAS. These genetic 
predictors of skin cancer (n=21) were examined to see if they have 
a higher effect size in renal-transplant recipients compared to non-
transplant populations.
For the candidate SNP analysis, a nominally significant association 
was found with a SNP in the MC1R gene (p= 0.0157). The variant 
was found to have the same direction of affect as described in the 
original study and the odds ratio was higher. The presence of one or 
more copies of the minor allele caused a significant decrease in time 
to developing skin cancer post-renal transplantation (hazard ratio 
= 2.06). We found a significant association in our GWAS between 
time to developing skin cancer post transplantation and a variant 
in SPOCK1 (p = 4x10-8). We found that heterozygote individuals 
developed skin cancer 7 times faster than wild type homozygotes. 
We will be carrying out further testing in other cohorts for validation 
of results.
This work is funded by Irish Research Council for Science, Engineering and 
Technology.
S10. The Irish DNA Atlas– a Study of Genetic Diversity in 
Ireland
E Gilbert1, S O’Reilly2, M Merrigan2, D McGettigan2, G Cavalleri1
1Molecular and Cellular Therapeutics, Royal College of Surgeons 
in Ireland, St Stephen’s Green, Dublin 2, Ireland, 2Genealogical 
Society of Ireland, 11, Desmond Avenue, Dún Laoghaire, Co. 
Dublin, Ireland.
Aims: The Irish DNA Atlas is a DNA collection being assembled 
with the aim of describing the fine-scale population structure 
in Ireland. Understanding such structure can inform on optimal 
design of clinical genetic studies as well as the history of the Irish 
population. We will present an overview of and the preliminary 
findings from the study.
Methods: We are recruiting individuals with all eight great-
grandparents born in Ireland, within 30 kilometres of each other. 
Participants are asked to complete a detailed birth-brief, which 
records place and date of birth of three generations of ancestors. 
We also collect some basic health-related details. DNA is extracted 
from a saliva sample. We have genotyped using an Illumina 
OmniExpressdense SNP genotyping platform. We present a number 
of analyses designed to visualise genetic structure, including; 
Principle Component, ADMIXTURE, and Runs of Homozygosity 
analysis.
Results: To date we have recruited 162 participants. The mean 
great-grandparental area is 32 kilometres, with an average great-
grandparental date of birth of 1850. Therefore the individuals in 
the Atlas provide insight to the genetic landscape of Ireland before 
significant movement of people from the 20th century onwards. 
An analysis of dense genotyping data from 142participants shows 
that the Atlas participants cluster closely with British individuals 
in a Europe wide PCA, but present different ancestral population 
components when compared with British, and other European 
populations. Irish individuals also present slightly higher levels of 
homozygosity relative to mainland European levels. PCA targeted 
at specific areas of interest within Ireland also hint at fine-scale 
substructure.
Conclusion: Ireland shows typical features of a homogenous 
population, well suited to the study of rare variation in disease risk.
S11.  Clinical and genetic predictors of patient response to 
lacosamide
SB Heavin1, M McCormack1, L Slattery1, N Walley2, A Avbersek3, 
J Novy3, S Sinha2, N Alarts4, B Legros4, R Radtke2, C Doherty4, 
C Depondt5, S Sisodiya3,D Goldstein6, N Delanty1,7, GL Cavalleri1
1Molecular and Cellular Therapeutics, Royal College of Surgeons 
in Ireland, Dublin, Ireland, 2Centre for Human Genome Variation, 
Duke University, North Carolina, USA, 3Department of Clinical and 
Experimental Epilepsy, Institute of Neurology, University College 
London, London, UK, 4School of Medicine, Trinity College Dublin 
and Department of Neurology, St James’s Hospital, Dublin, Ireland, 
5Department of Neurology, Hôpital Erasme, Université Libre de 
Bruxelles, Brussels, Belgium 6Institute for Genomic Medicine, 
Columbia University, New York, USA, 7Division of Neurology, 
Beaumont Hospital, Dublin, Ireland
There are ~37,000 people in Ireland living with epilepsy. Anti-
epileptic drugs (AEDs) control seizures in up to 70% of patients. 
Lacosamide (LCM) is an AED that is licenced for the treatment 
of focal-onset seizures.  We aimed to determine the clinical 
and genetic predictors of LCM responsive and non-responsive 
patients.  A total of 483 patients, who were previously refractory 
to medication, were recruited from four tertiary epilepsy referral 
centres: Dublin, Ireland; London, UK; Brussels, Belgium; North 
Carolina, USA.  Response to LCM was determined according to 
four categories; (i) seizure freedom, (ii) ≥75% reduction in seizure 
frequency, (iii) seizures worsening and (iv) no response. Overall, 
13% of patients showed a positive response (seizure freedom or 
≥75% reduction in seizure frequency) to LCM treatment. Response 
varied depending on epilepsy diagnosis, with idiopathic generalised 
epilepsy (also known as genetic generalised epilepsy) emerging 
as a potential target group for LCM treatment.  An adverse drug 
reaction causing discontinuation of LCM treatment was recorded 
in 19% of patients.  Genome wide association (GWAS) and whole 
exome sequencing (WES) was used to investigate the importance of 
genetic variation in predicting LCM response. Analysis of common 
variation via GWAS pointed to a locus containing the KALRN gene 
as potentially predictive of membership to the seizures worsening 
group.  Analysis of rare variation via WES did not identify any 
additional variant or gene associated with particular LCM response 
groups.
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S12.  Unfolded Protein Response in a mouse model of 
Messmann’s Epithelial Corneal Dystrophy
MA Nesbit1, DG Courtney1, EHA Allen1,2, SD Atkinson3, E Maurizi1, 
JE Moore4,DM Leslie Pedrioli2, WHI McLean2, CBT Moore1
1School of Biomedical Sciences, University of Ulster, Coleraine, 
Northern Ireland, 2Dermatology and Genetic Medicine, Colleges of 
Life Sciences and Medicine, Dentistry & Nursing, University of 
Dundee, Dundee, Scotland, 3Northern Ireland Centre for Stratified 
Medicine, CTRIC, Altnagelvin Hospital Site, Derry/L’Derry, 
Northern Ireland, 4Cathedral Eye Clinic, Belfast, Northern Ireland
Corneal dystrophies are a group of blinding inheritable conditions 
with a collective worldwide incidence of 1 in 2,000. Meesmann’s 
epithelial corneal dystrophy (MECD) is a rare autosomal dominant 
disorder with phenotypes of varying severity ranging from 
asymptomatic to foreign body sensation, photophobia, presence of 
anterior epithelium microcysts and corneal scarring. It is caused by 
dominant-negative heterozygous missense mutations found within 
the KRT3 or KRT12 genes encoding the cytoskeletal keratins K3 
and K12. To investigate the pathomechanism of this disease we 
generated and characterized a novel knock-in humanised mouse 
model carrying the MECD-associated Leu132Pro mutation.
Although no overt changes in corneal opacity were detected by 
slit-lamp examination, heterozygous mice exhibited a subtle 
histological and ultrastructural phenotype of cell fragility within the 
corneal epithelium, which was greatly exaggerated in homozygous 
animals. Mutant corneal epithelial cells were larger, contained 
prominent intracellular spaces and showed overt cytolysis with 
occasional cell rupture at the corneal surface.
Immunohistochemical analysis showed that the humanized mutant 
K12 protein was expressed specifically in the anterior corneal 
epithelium and revealed an altered keratin expression profile in the 
cornea of mutant mice that was confirmed by quantitative Western 
blot analysis.
Analysis of expression of unfolded protein response (UPR) markers, 
Caspase 12 and DDIT3, revealed up regulation of both markers in 
homozygous mice and DDIT3 in the heterozygous mice. A TUNEL 
assay revealed that the apoptotic rate in the mutant cornea was 
increased 17–fold compared to the wild type (p<0.001).
Thus, we have developed a novel mouse model for MECD, which 
up-regulates UPR pathways that will be a valuable resource for 
development of therapeutics targeting dominant-negative corneal 
dystrophies.
POSTER PRESENTATIONS:
P01. A Neurofibromatosis type 1 database for ROI
CW Kirk1, A Green1
1Department of Clinical Genetics, Our Lady’s Children’s Hospital 
Crumlin, Dublin 12
Neurofibromatosis type 1 (NF1) is a multisystem variable genetic 
condition that causes benign tumours in various organs, mainly 
the skin, eyes and brain. Other associated health complications are 
epilepsy, scoliosis, learning difficulties and autism. Our aim was 
to set up a database of the NF1 patients who had been through 
our Service since it was set up in 1995, detailing how they were 
affected by the condition. We run a fortnightly NF clinic that is 
funded by NF Ireland. We used the database template that is used 
in the Belfast NF clinic.
A cohort of 575 patients with NF1 was recorded on the database on 
20/02/2015. The prevalence of NF1 is reported to be 1/3000 live 
births and based on the estimated population there should be 1,600 
individuals with NF1 in ROI.
We identified 13 women with NF1 who were in their 40’s and 
warranted breast surveillance. With their permission, we wrote to 
their GPs requesting that this be put in place.
We also identified 24 individuals who would be transitioning from 
Paediatric to Adult services. We wrote to them offering a Genetics 
Consultation to discuss screening for adults with NF1 and the 
genetics of the condition. So far, 5 have accepted this offer.
Already this database is proving to be a useful tool for monitoring 
and identifying NF1 patients who may benefit from screening and/
or Genetics review. Also, recording the clinical features of NF1 
patients will help us to identify those patients with complex NF1 
who require Specialist input.
P02.  Titin Truncating Variants are common in patients with 
myocardial infarction and low ejection fraction
G Rea 1,2, J Petyrka3, M Vieira3 ,JS Ware1,2, R Walsh1,2,  S John 2 , 
S Prasad3, R Buchan2, S Wilkinson2, S Prasad2,,PJR Barton1,2, SA 
Cook1,2,3
1Heart and Lung Institute, Imperial College, London SW3 6LY, 
UK, 2NIHR Cardiovascular Biomedical Research Unit, Royal 
Brompton and Harefield NHS Foundation Trust, London SW3 6NP, 
UK, 3Department of Cardiology, National Heart Centre Singapore, 
Singapore 168752, Singapore
The Titin gene is a major determinant of myocardial function and 
its importance in familial and ‘idiopathic’ Dilated Cardiomyopathy 
(DCM) has recently been ascertained. We hypothesize that patients 
with pronounced left ventricular dysfunction following myocardial 
infarction (MI), when controlling for infarct parameters and 
coronary anatomy, may have a high burden of TTN truncating 
variants (TTNtvs). We studied a large cohort (n=335) of post-
MI patients. Gadolinium-enhanced Cardiac Magnetic Resonance 
(CMR) was used to characterise cardiac dimensions, function and 
tissue properties, the size and thickness of MI were quantified using 
a standard 17-segment model. Targeted re-sequencing of TTN was 
performed. Genetic variation in TTN in 430 ethnically matched 
healthy volunteers along with public repositories, were used for 
variant annotation and comparison.  Our analyses show that out of 
the 335 post-MI patients, nine (2.7%; ~1 in 35 post-MI cases) had a 
TTNtv. Patients with a TTNtv had a significantly lower LVEF than 
those without (31.2±13.9% vs. 41.2±14.7%; p=0.026). An LVEF 
<30% is used to guide device therapy in post-MI patients and as 
hypothesized, TTNtv were significantly enriched in this group 
compared to MI patients with higher LVEFs (6.98% vs. 1.21%, 
p=0.01). These data identify a novel role for truncating variants in 
TTN, a DCM gene, in post-MI systolic dysfunction. Intriguingly, 
the effect size of the TTNtv is equal or greater than many of the 
infarct covariates used to guide re-vascularisation therapy. Based on 
these findings it will be important to explore if genetic stratification 
of the post-MI patient can inform treatment strategies.
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P03.  The extent of Lymphangioleiomyomatosis (LAM) in the 
Tuberous Sclerosis (TS) population in NI
DE Donnelly1, T O’Neill1, R Hardy1, PJ Morrison1
Belfast Health & Social Care Trust, Belfast.
Lymphangioleiomyomatosis (LAM) is a multisystem disease 
affecting, almost exclusively female, TS patients.  It is characterised 
by cystic lung destruction and symptoms occur from the 2nd or 3rd 
decade onwards.  Recently, new treatments, e.g. mammalian target 
of rapamycin (mTOR) inhibitors, have been found to be effective. 
It is important that women are screened for symptoms for this 
condition to allow for early intervention.  We have 43 women with 
TS over the age of 18 years.  All were sent out a questionnaire 
regarding respiratory symptoms, treatment and follow-up to 
determine the extent of LAM in our population.  We aim to use this 
data to improve screening for LAM in our regional TS clinic.
P04.  Connexin 26/30 & deafness: our experience of 5 years
M Hegarty1, M Irvine1, T Dabir2
1Queen’s University, Belfast, 2Medical Genetics Department, 
Belfast City Hospital, BT9 7AB
Congenital hearing loss is the most prevalent and genetically 
heterogenous sensorineural disorder. Around 50% congenital 
hearing loss in genetic in nature and can be syndromic (30%) or non 
syndromic (70 %).  Autosomal recessive non syndromic deafness 
is the commonest cause of genetic hearing loss predominantly 
related to connexin 26/30 genes.  The genetic forms of hearing loss 
are diagnosed by otologic, audiologic, and physical examination, 
family history, ancillary testing (e.g. temporal bone CT, ECG), and 
molecular genetic testing.  In the absence of a specific diagnosis, 
empiric recurrence risk coupled with connexin 26/30 results is 
used for genetic counselling. We analysed our data of past 5 years 
(2010-14) of connexin 26/30 gene mutation analysis.   Connexin 
26/31 gene mutation analysis was done in 61 individuals. Fifteen 
had developmental delay and/or dysmorphism and eighteen had 
other genetic investigations either pre or post connexin 26/30 
testing. Temporal bone imagining and ECG was not done routinely 
.Three had array CGH identified chromosomal abnormality, two 
had confirmed diagnosis of   Pendred syndrome and three were 
investigated for Waardenburg syndrome. Connexin 26/30 mutation 
related deafness was identified in 8 individuals (13%). Five were 
homozygous for 35delG and three were compound heterozygous. 
All the mutation positive individuals had bilateral, prelingual, 
severe to profound SNHL with no dysmorphism or developmental 
delay excluding the speech. The antenatal and postnatal history 
was not significant and the inner ear imaging was normal.  When 
these characteristics were taken into consideration the diagnostic 
yield improved to 22 % highlighting the phenotype associated with 
Connexin 26/30 related hearing loss.
P05.  Initial experience on transportation based PGD/PGS in 
Ireland
X Zhang1, T Dineen1, J Flanagan1, A Kovacs1, R Mihart1, J 
O’Callaghan1, J Culligan1, N Daly1, D McAuliffe1, J Waterstone1
Preimplantation genetic diagnosis/screening (PGD)/ (PGS) is a 
reproductive option for couples at risk of a genetically abnormal 
pregnancy. This study reviews the outcome of all biopsy cycles 
performed at Cork Fertility Centre (CFC) since the programme 
began.
Embryo biopsy and embryo transfer procedures were performed 
at CFC while genetic analysis of the biopsy cells was carried out 
at Reprogenetics, UK. Biopsied embryos were cryopreserved by 
vitrification. Unaffected embryos were warmed and transferred in 
a subsequent frozen embryo transfer (FET) cycle. Seven couples 
have completed a PGD/PGS cycle at CFC, five for single gene 
disorders, (cystic fibrosis-3 cases, Mucolipidosis and Smith-Lemli-
Opitz Syndrome). The other two couples underwent PGS.
In total, 39 embryos were biopsied, 15 on day 3 (one cycle) and 24 
on day 5/6.No logistic failures were found during the biopsy sample 
transportation. Genetic defects were detected using multiplex-PCR, 
karyomapping, and array CGH. Polymorphisms were used to 
confirm diagnosis, and detect chromosome abnormalities. Genetic 
testing identified 15 unaffected and 19 affected embryos with 
single gene disorders. 12 blastocysts (54.5%) were chromosomally 
euploid.
Seven out of eight unaffected embryos survived after warming and 
were transferred in 6 FET cycles.  Four pregnancies resulted -two 
live births, two ongoing pregnancies- an implantation rate of 57%.
Combining blastocyst biopsy with vitrification appears to be an 
effective strategy for transportation PGD/PGS. The on-going 
pregnancy rate suggests that a transport PGD/PGS programme can 
be an effective reproductive option for couples seeking genetic 
testing of embryos prior to implantation.
P06.  Investigating the role of a single nucleotide polymorphism 
at 9q22.23 in Thyroid Cancer Predisposition: A Case-Control 
Study
TP McVeigh1,2, P Owens2, N Miller2, C Guerin3, D Quill4, M Bell4, 
AJ Lowery2,4, MJ Kerin2,4
1Department of Clinical Genetics, Our Lady’s Children’s Hospital, 
Crumlin, 2 Discipline of Surgery, National University of Ireland 
Galway, 3Department of Endocrine Surgery, Hospital de la Timone, 
Marseilles, France, 4Galway University Hospital, Ireland
FOXE1 is an intronless gene located on chromosome 9q22.23. 
FOXE1 plays a crucial role in thyroid morphogenesis. Mutations 
in FOXE1 are associated with a number of thyroid pathologies, 
namely hypothyroidism, athyroidism and thyroid cancer.
This study aims to investigate the frequency and impact of a single 
nucleotide polymorphism G>A at 9q22.23 in a Western European 
cohort of patients with thyroid cancer compared to controls. 
DNA was extracted from buccal swabs or whole blood of patients 
with differentiated non-medullary thyroid cancer by ethanol 
precipitation. Patients were recruited from two tertiary referral 
centres in Ireland and France. Cancer-free controls were recruited 
from the community. Genotyping was performed using Taqman-
based PCR. Data was analysed using SPSS V22.
One hundred and eighty one cases and eighty-three controls were 
genotyped for the variant. The frequency of the minor allele among 
cases was 0.46 compared to 0.30 among controls. Genotypic 
frequencies and odds ratios are outlined in the table. The variant 
was identified in patients with thyroid cancer significantly more 
frequently than controls in both heterozygous and homozygous 
forms. This supports the role of this variant in thyroid predisposition. 
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Control 41 34 8
Case 49 98 34





P07.  A qualitative analysis of the attitudes of Irish patients 
towards participation in genetic-based research
TP McVeigh1,2, KJ Sweeney3, MJ Kerin2, DJ Gallagher4,5
1Department of Clinical Genetics, Our Lady’s Children’s Hospital 
Crumlin, Dublin,  2Discipline of Surgery, National University of 
Ireland, Galway, 3BreastCheck, Western Unit, Galway University 
Hospital, 4Mater Misericordiae University Hospital, Dublin, 5St 
James’s University Hospital, Dublin 
Background: Progress in diagnostic and therapeutic strategies in 
medicine is dependent upon high-quality biomedical research. 
Translation of research findings into the clinic relies on patient 
participation in innovative clinical trials. We investigated attitudes 
to genetic research in Ireland, in particular with respect to 
commercial and financial implications.
Methods: A multi-centre cross-sectional survey study was 
performed. Consecutive patients attending four out-patient clinics 
were asked to complete paper-based questionnaires. An electronic 
version of the same questionnaire was created on Survey Monkey 
with a link made public on a social media website for a period of 24 
hours. Data was analysed using SPSS.  
Results: 351 questionnaires were completed (99 paper, 252 
electronic). The majority of respondents were female (n=288, 82%), 
and highly educated, with 244 (70%) attending college/university. 
Most participants supported genetic research (267, 76%), more 
frequently for common diseases (274, 78%) than rare disorders 
(204, 58%, p<0.001, x2). 103 (29%) had participated in scientific 
research, and 57(16%) had donated material to a bio-bank. The 
majority (n=213, 61%) would not support research with potential 
financial/commercial gain. 106(30%) would decline to participate 
in research if researchers would benefit financially, compared 
to 49(14%) if the research was supported by a pharmaceutical 
company, (p<0.001, x2).  Respondents would provide buccal 
samples (258, 74%) more readily than tissue (225, 64%) or blood 
(222, 63%).  
Conclusion: A high level of support for genetic research exists 
among the Irish population, but active participation is dependent 
upon a number of factors, notably, type of biological material 
required, frequency of the disease in question, and commercial 
interest of the researchers. 
P08.  Pedigree Drawing in the Department of Clinical Genetics: 
An Audit of Adherence to International Recommendations
TP McVeigh1, L Bradley1
1Dept. of Clinical Genetics, Our Lady’s Children’s Hospital, 
Crumlin, Dublin
A pedigree is the symbolic language of clinical genetic services and 
a visual representation of a family’s medical history and genetic 
relationships. It assists diagnosis, identification of relatives at risk, 
and is a crucial tool in identifying inheritance patterns of genetic 
disorders. We aimed to examine adherence of clinical genetics 
professionals of the Department of Clinical Genetics (DCG) to 
international guidelines for pedigree drawing. 
A retrospective chart review of pedigrees drawn in 102 consecutive 
outpatient appointments in October 2014 was undertaken. Each 
pedigree was scored using a standardised proforma adapted from 
international guidelines.  Data was recorded with respect to referral 
type, legibility and pedigree complexity. 
Pedigrees were completed in 98(96%) charts. The median score 
obtained was 10/20(2-16).  Pedigree identifier was recorded in 
30(31%). Sixty-one (62%) pedigrees were signed, and 57(58%) 
dated. The proband was identified in 34(35%), with date of birth 
(DOB) recorded in 32(32%). First degree relatives (FDRs) DOBs 
were stated for 24(25%), and age only in 31 (32%).  Ethnicity was 
recorded in 13(13%). Presence/absence of consanguinity was noted 
in 24 (24%). The majority of pedigrees included ≥3 generations 94 
(96%), including a median of 22 (3-66) individuals. 
Although the majority of pedigrees contained large volumes of data 
on multiple individuals across multiple generations, deficiencies 
were identified in specific areas. While pedigree drawing should 
be a standard competency for all healthcare professionals, genetic 
professionals’ standards should be exemplary. Results were 
presented at a Departmental Clinical Meeting, impediments to 
adherence with guidelines identified and recommendations for 
improvement discussed.  Re-audit is currently ongoing.
P09.  Beware of the genome 
J Casey1,2, DE Barton2,3, SA Lynch1,2,3
1Genetics Department, Temple Street Children’s University 
Hospital, 2UCD School of Medicine & Medical Sciences, 
3Department of Clinical Genetics, Our Lady’s Children’s Hospital, 
Crumlin.
Exome and genome sequencing are being hailed as important 
tools in diagnostics and personalised medicine. This technology 
has already integrated into some aspects of mainstream medicine 
in Ireland. But are we overlooking the scale of the challenges and 
pitfalls that these tests present? Here, we discuss a number of issues 
that we have encountered during our research studies.
Incidentals and VOUS: The European Society of Human Genetics 
advocates for stringent filtering of data to minimise the risk of 
incidental findings. However, our research shows that incidental 
findings can still occur, despite using stringent filters. Counselling 
can be difficult even in cases where the incidentals are of proven 
pathogenicity. Furthermore, a large proportion of incidentals are 
variants of unknown significance (VOUS), making interpretation 
and reporting very challenging. Should we act on VOUS? And at 
what cost to the healthcare system?
Misclassified variants: Our understanding of how genetic variants 
impact our health is still in progress. It is not surprising that recent 
studies are showing that variants originally reported as pathogenic 
are actually benign. As new information emerges, it is possible that 
variant classification will change. What are the implications for 
patient counselling?
Filtering: There are numerous tools and databases available for data 
filtering. It is now becoming evident that different analysis tools 
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give different results. The lack of standardisation could pose a 
significant problem, particularly in a clinical setting?
Whilst exome/genome sequencing has significant potential to 
improve diagnostic yield, it is important that all stakeholders 
are aware of the potential pitfalls and challenges to ensure safe 
implementation of this new technology.
P10.  YouTube, animation and genetic education
SA Lynch1, J Matthews1 J Turner2, J Casey1
1University College Dublin, 2Genetics Dept., Our Lady’s Children’s 
Hospital, Crumlin, Dublin
We have developed a number of short videos, some animated, to 
help develop integrated online genetic education. Our vision is to 
develop core videos on topics such as pedigree drawing, genetic 
cascade and predictive testing, exome/genome sequencing, 
incidental findings and ethics, relevant to practises in Ireland. 
Outside of the core, we have specialist topic videos relevant to 
genetics, created by colleagues from diverse disciplines.  Our 
target audience are health care professionals from all aspects of 
mainstream medicine. 
Much of our content, such as our six animated videos, are freely 
available on YouTube. These videos already have ~30,000 views. 
Families can view them prior to an appointment.
We found that short videos (~5 minutes) are more popular; the 
viewer stays with the video through its entirety in contrast to long 
videos. As viewers post thumbs up and thumbs down as well as 
comments, this is a useful way of gaining prompt feedback. Our two 
recent chromosome translocation videos have already had >18,000 
views and links to the ESHG website have been provided. We are 
translating these videos into ten languages to increase applicability. 
http://bit.ly/RecipTranslocation & http://bit.ly/RobsTranslocation
Feedback includes: “Wow this video was more helpful than any 
other genetic video on YouTube” and “Now I understand it thanks”. 
Whilst YouTube is used by the public to access genetic information, 
much of the educational content is aimed as researchers. There is 
a market for simple genetic information to be developed for the 
public.
Grants: UCD; Temple Street children’s fund for Health; Shire Pharmaceuticals
P11.  A Case of Metaphyseal Chondromatosis with D-2 
Hydroxyglutaric Aciduria
JJ O’Byrne1, PE Fitzsimons2, S Unger3, J Croft4, PD Mayne2, E 
Moylette5, C McDonnell6, SA Lynch1
1Department of Clinical Genetics, Our Lady’s Children’s Hospital 
Crumlin, Dublin, Ireland, 2National Centre for Inherited Metabolic 
Disorders, Temple Street Children’s University Hospital, Dublin, 
Ireland, 3Centre Hospitalier Universitaire Vaudois, Lausanne, 
Switzerland, 4Department of Clinical Chemistry, Sheffield 
Children’s Hospital, Sheffield, United Kingdom, 5Department 
of Paediatrics, Galway University Hospital, Galway, Ireland, 
6Department of Endocrinology, Temple Street Children’s University 
Hospital, Dublin, Ireland.
A developmentally appropriate thirteen month old girl, born to non-
consanguineous Irish parents, presented with asymmetry or an extra 
crease in the midshaft of her right arm and relative short stature 
(occipitofrontal circumference - 91st centile, weight - 50th-75th 
centile, Length - 0.4th-2nd centile). A radiograph of the arm followed 
by a skeletal survey revealed bilateral symmetrical irregularities of 
the metaphyses of the humeri (proximal), femora (proximal and 
distal), and tibiae (proximal and distal) with less marked changes in 
the fibulae, feet and phalanges. Irregular chondral dysplastic changes 
in the left iliac blade were also noted. The epiphyses were spared, 
the skull, vertebrae, ribs, clavicles were unremarkable and bone 
age was normal. Urinary D2-Hydroxyglutarate was approximately 
55 times the normal level confirming a diagnosis of metaphyseal 
chondromatosis with D-2 hydroxyglutaric aciduria. This is likely 
due to somatic mutations in the isocitrate dehydrogenase gene 
which is currently under analysis. The prognosis is guarded and 
the recurrence risk is considered to be <1%. This case highlights 
1: an unusual combination of characteristic skeletal and metabolic 
abnormalities which has rarely been reported and 2: the importance 
of performing urine organic acid in patients who present with 
generalized enchondromatosis.
P12.  Segmental overgrowth syndromes caused by somatic 
mosaic mutations in PIK3CA
JJ O’Byrne1, VE Parker2, M Al-Shehhi1, PM Kelly3, C Costigan4, A 
Hegarty1, R Knox2, S Byrne5, DR Betts1, LRK. Semple2, L Bradley1, 
AJ Green1, A Irvine6, SA Lynch1
1Department of Clinical Genetics, Our Lady’s Children’s Hospital, 
Patient Age and Sex




Other findings Gene Mutation
2 year old boy
Left Leg (particularly 4th and 
5th toes) No No
PIK3CA (H1047L)
Left leg (10-20 % cells)
Right leg (0% cells)
16 year old girl Generally Overgrown, Right hemihypertrophy Mild Capillary Malformation
PIK3CA (E418K)
Right arm (50% cells)
Left arm (25% cells)
6 week old girl Right Foot No Displaced bones in foot Result awaited
13 month old girl Macrocephaly No Polymicrogyria Result awaited
16 year old boy
Generally overgrown, left 
side larger than right  below 
neck, opposite above neck
Mild Capillary Malformation Result awaited
3 year old boy Hemimegalencaphaly Mild/Moderate Naevus flammeus Result awaited
11 month old girl Right leg No Right Hydronephrosis Result awaited
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Crumlin, Dublin, 2The University of Cambridge Metabolic Research 
Laboratories, Institute of Metabolic Science, CambridgeCB2 0QQ, 
UK, 3Department of Paediatric Orthopaedics, Our Lady’s Children’s 
Hospital, Crumlin, Dublin, 4Department of Paediatric Diabetes and 
Endocrinology, Our Lady’s Children’s Hospital, Crumlin, Dublin, 
5Department of Paediatric Orthopaedics, Children’s University 
Hospital, Temple Street, Dublin, 6Department of Dermatology, Our 
Lady’s Children’s Hospital, Crumlin, Dublin
Segmental overgrowth syndromes are rare, poorly classified 
disorders which carry a significant burden of morbidity and mortality 
that pose diagnostic, prognostic and management challenges. 
Recently, somatic mutations in the phosphatidylinositol-3-kinase/
AKT/mTOR [PROS] cellular signalling pathway have been shown 
to underline many overgrowth disorders. We present 7 cases of 
segmental overgrowth presenting with wide phenotypic variation 
(see Table). Pathogenic somatic mutations in PIK3CA were 
identified in two cases to date. Genetic analysis is awaited on the 
other four cases. Such cases are reclassifying segmental overgrowth 
disorders and helping the development of targeted therapies such 
as mTOR inhibitors. A collaboration with Cambridge University 
is facilitating a further 35 cases of segmental overgrowth to be 
enrolled for investigation and possibly inclusion in a treatment 
clinical trial.
P13.  Microdeletion/microduplication of the proximal 15q11.2 
(BP1-BP3) region: an emerging susceptibility locus
L McArdle1, J McDaid1, H Ryan1, A Dunne2, DR Betts1
1The Department of Clinical Genetics, Our Lady’s Children’s 
Hospital Crumlin, Dublin, Ireland. 2Griffith University, Gold Coast 
Campus, Queensland, Australia
The proximal long arm of chromosome 15 contains clusters of 
LCRs located at five common breakpoint sites, referred to as BP1-
BP5. This region is susceptible to rearrangements mediated by 
non-allelic homologous recombination which results in various 
deletions and duplications. Two common classes of deletions are 
described in individuals with Prader-Willi /Angelman syndrome 
(PWS/AS). PWS/AS deletion is flanked by either proximal BP1 
or BP2 and the more distal BP3. Individuals with PWS/AS with 
Type I deletions (BP1-BP3) have been reported with more severe 
phenotype than individuals with Type II deletions (BP2-BP3). 
The BP1-BP2 region spans approximately 500kb and contains 
four highly conserved genes, TUBGCP5, NIPA1, NIPA2 and 
CYFIP1; TUBGCP5 is expressed in subthalamic nuclei while 
the latter three genes are widely expressed in the central nervous 
system. Recent studies have suggested an association between 
BP1-BP2 deletions/duplications with an abnormal clinical 
phenotype including dysmorphisms, speech and motor delay, 
autism, behavioural problems and seizures. However, imbalances 
in this region have also been seen in the normal population and in 
mildly affected carriers suggesting that the region contains genetic 
material associated with incomplete penetrance. We identified 27 
patients with imbalances within the proximal 15q11.2 (BP1-BP2) 
region, all presenting with various degrees of developmental delay. 
Analysis was conducted using a high resolution microarray-based 
comparative genomic hybridization (aCGH). Parental studies were 
carried out where possible. The results presented here indicate that 
15q11.2 BP1-BP2 copy number changes may increase susceptibility 
to neurodevelopmental problems. 
P14.  Orphanet Ireland : Mapping Ireland’s Rare Disease 
Activity
DM Lambert1, EP Treacy1,2
1National Rare Diseases Office, Mater Misericordiae University 
Hospital, Dublin 7, 2National Clinical Programme for Rare 
Diseases, HSE
Orphanet is an international information portal for rare disease 
(RD) activity. 39 countries participate in rare diseases data 
collection, with over 41,000 daily site hits to www.orpha.net from 
over 200 countries.  Disease summaries are written by experts and 
link to more detailed information.  Data collected includes clinical 
expert centres, medical laboratories, patient organizations, research 
projects, registries, clinical trials and biobanks; as well as reports on 
RD prevalence and orphan drugs.
Orphanet Ireland is funded by the EC 3rd Joint action on RD and the 
HSE, and located at the National Rare Diseases Office. Our short 
term goal is to ensure the accuracy of the existing Irish data, then 
to create a comprehensive rare disease resource database within the 
next 2 years.    
Data on all RD activity can be self-declared by clinicians, 
researchers and patient organizations but is verified and validated 
by the Orphanet Ireland to ensure it meets inclusion criteria. Data 
will also be collected from departmental and professional websites, 
regulatory and funding bodies, as well as direct contact with 
professionals. 
The aim of centralizing Irish rare disease information is 1: to 
provide a resource to clinicians and patients looking for or with a 
new RD diagnosis, and 2: to promote links between professionals 
and the patients concerned, within and between countries. Orphanet 
Ireland will serve as the unifying platform for RD activity for 
designation of centres of expertise (ongoing) and of laboratories 
and researchers participating in Reference Networks (from 2016) to 
fulfil Ireland’s European and Cross Border Directive requirements. 
P15. miR-24 regulates p27 expression in prostate cancer
SM Lynch1, MM McKenna2, CP Walsh1, DJ McKenna1
1Biomedical Sciences Research Institute, University of Ulster, 
Coleraine, N. Ireland, UK, 2Department of Cellular Pathology, 
Western Health & Social Care Trust, Altnagelvin Area Hospital, 
Derry, N. Ireland, UK
MicroRNAs (miRNAs) are small, non-coding RNA molecules with 
an important role in cancer. In prostate cancer, several miRNAs are 
expressed abnormally suggesting they may be useful markers for 
diagnosis, prognosis, and potential therapeutic intervention in this 
disease. In this study we used PCR to investigate the expression 
of miR-24 in a panel of prostate cancer cell-lines and in a series 
of clinical prostate biopsy specimens. The biological significance 
of miR-24 expression in prostate cancer cells was assessed by a 
series of in vitro bioassays and the effect on proposed targets p27 
(CDKN1B) and p16 (CDK2NA) was investigated. We showed that 
miR-24 expression was significantly lower in prostate cancer cell 
lines compared to a normal prostate epithelial cell line. Decreased 
expression of miR-24 was also more frequently observed in both 
needle core and prostatectomy tumour tissue relative to matched 
normal tissue. Low miR-24 expression correlated with high PSA 
serum levels and other markers of increased prostate cancer 
progression. Importantly, over-expression of miR-24 inhibited 
cell cycle, proliferation, migration and clonogenic potential of 
prostate cancer cells, as well as inducing apoptosis. p27 and p16 
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were confirmed as targets of miR-24 in prostate cancer cells and 
a significant inverse correlation between miR-24 and p27 was 
revealed in clinical prostatectomy specimens. These findings 
provide evidence that miR-24 has a tumour suppressor role in 
prostate cancer and also targets p27 and p16 in prostate cancer cells. 
We propose that it may be a useful progression biomarker or focus 
of therapeutic intervention for this disease.
P16.  Cognitive analysis of schizophrenia risk genes: focus on 
genes with epigenetic function
LWhitton1, D Cosgrove1, C Clarkson2, M Gill3, A Corvin3, S Rea2, 
G Donohoe1, D Morris1
1Centre for Neuroimaging and Cognitive Genomics (NICOG), 
Discipline of Biochemistry and School of Psychology, National 
University of Ireland, Galway, 2 Centre for Chromosome Biology, 
Discipline of Biochemistry, National University of Ireland, Galway, 
3Neuropsychiatric Genetics Research Group, Institute of Molecular 
Medicine and Discipline of Psychiatry, Trinity College Dublin.
Schizophrenia is a psychiatric disorder characterised by positive 
and negative symptoms as well as cognitive impairment. Disrupted 
epigenetic processes are observed in complex and single gene brain 
disorders that exhibit cognitive deficits, and have been recently 
studied as potential targets of pharmaceutical intervention for the 
treatment of cognitive deficits.
Genome wide association studies (GWAS) have identified 108 
chromosomal regions associated with risk of schizophrenia, 
implicating 350 genes. The aim of this study was to identify risk 
genes for schizophrenia with epigenetic functions and test these 
genes for association with cognitive deficits in schizophrenia. Cross-
referencing 535 epigenetic genes with 350 GWAS genes identified 
5 candidate genes: RERE, SATB2, EPC2, EP300 and KDM3B. 
The effect of risk single nucleotide polymorphisms (SNPs) in these 
genes on cognition was examined using a dataset of psychosis 
cases (n = 905) and controls (n = 330) who had completed tests in 5 
areas of cognition: IQ, working & episodic memory, attention and 
social cognition. Regression was carried out using a linear model. 
For RERE, there was association between the schizophrenia risk 
allele and attention (p = 0.03). For SATB2, there was association 
with social cognition (p = 0.003). For EPC2, an association was 
found with full scale IQ (p =0.004) and performance IQ (p = 0.001). 
An association was found between the schizophrenia risk allele for 
KDM3B and verbal IQ (p = 0.038). This initial analysis provides 
support for our hypothesis that risk genes with epigenetic functions 
contribute to cognitive deficits in schizophrenia.
P17.  Do Irish periodic paralysis patients have a common 
genetic origin?
J Neville1, AM Ryan2, CK Hand1
1Department of Pathology, University College Cork, 2National 
Neuroscience Centre, Cork University Hospital and University 
College Cork
Periodic Paralyses (PPs) are rare autosomal dominantly inherited 
skeletal muscle channelopathies characterised by episodic 
weakness secondary to abnormal muscle excitability. PPs are 
broadly classified into hyperkalaemic (HyperPP) or hypokalaemic 
(HypoPP) based on serum potassium (K+) levels. HypoPP is caused 
by mutations in CACNA1S and SCN4A awhile the less frequent 
HyperPP is generally caused by SCN4A gene mutations.
We have recruited a growing cohort of Irish PP patients for which 
comprehensive clinical and genetic data has been gathered. We 
believe that this group of PP patients are phenotypically and 
genetically distinct. Firstly, contrary to publications, we have 
detected more HyperPP than HypoPP. Secondly, we have detected 
only one of the common SCN4A gene mutations and finally each 
of the patients is unusual clinically with attacks of longer duration 
and increased severity.
The aim of this project is to investigate this group of Irish periodic 
paralysis patients in which the same gene defect has been described 
to determine whether there is a common genetic background.
We will use haplotype analysis of polymorphic microsatellite 
markers in the SCN4A gene region to determine if there is a shared 
genomic region.
We will present the results of this study and discuss the implications 
for the diagnosis and management of these patients.
P18.  PCR-RFLP assay for the detection of LHON Mutations
E Ryan1, F Ryan2, D Barton3, V O’Dwyer1, D Neylan2
1National Optometry Centre, Dublin Institute of Technology, Kevin 
Street, Dublin 8, Ireland, 2School of Biological Sciences, Dublin 
Institute of Technology, Kevin Street, Dublin 8, Ireland, 3Centre for 
Medical Genetics, Our Lady’s Hospital for Sick Children, Crumlin, 
Dublin 12, Ireland.
Leber hereditary optic neuropathy (LHON) is one of the most 
common inherited optic neuropathies with an incidence of up to 1 in 
31,000 worldwide and results in significant visual morbidity among 
young adults. The disorder is the result of mitochondrial dysfunction 
and results from primary mitochondrial DNA mutations affecting 
complex I subunits of the respiratory chain. Approximately 95% 
of LHON patients will have one of 3 mitochondrial mutations, 
G3460A (13%), G11778A (69%) and T14484C (14%) in NADH 
Dehydrogenase subunits 1, 4 and 6 respectively with other rare 
mutations accounting for the final 5%. Visual recovery can occur 
in some LHON patients but the extent of the visual recovery is 
influenced by the mutation involved, highlighting the need for a 
simple robust and cost effective mutation detection strategy.
The 3 common mutations are typically identified by individual 
end-point PCR-RFLP, ARMS PCR or PCR followed by Sanger / 
Pyrosequencing. This study developed a multiplex PCR-RFLP 
assay to detect the 3 common LHON causing mutations in a single 
tube format.
Primers, based on the reference sequence NC_012920.1, were 
designed to incorporate a MaeIII restriction site in the presence 
of the 3460A, 11778A and 14484C mutations and the multiplex 
assay reliably detected the 3 mutations in LHON patient DNA and 
in synthetic LHON controls harbouring the 3 common mutations 
cloned into plasmids.
In conclusion, we developed a simple cost effective assay to detect 
95% of LHON causing mutations and developed a set of cloned 
controls providing an unlimited patient free resource for LHON 
testing.
P19.  Targeting hypoxia in prostate cancer cells to increase 
treatment efficacy
H Nesbitt1, NM Byrne2, J Worthington3, SR Mc Keown1, DJ Mc 
Kenna1
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1Biomedical Science Research Institute, University of Ulster, 
Cromore Road, Coleraine, Londonderry, BT52 1SA, Northern 
Ireland, 2Bone Biology Division, Garvan Institute of Medical 
Research, Darlinghurst, Sydney, Australia,  3Axis Bioservices Ltd, 
Research Laboratory, Castleroe Road, Coleraine, Londonderry, 
BT51 3RP, Northern Ireland.
Androgen deprivation therapy e.g. bicalutamide (BCA) is widely 
used to treat advanced prostate cancer; however, within 1.5-3 
years most tumours have progressed to androgen independence 
(Abate-Shen C; Genes Dev 14, 2410-2434; 2000). Previously 
we showed that daily BCA causes an initial profound hypoxia 
(<0.1%) in LNCaP tumours that recovered after ~17 days. This 
was accompanied by progression to a more malignant phenotype 
indicating hypoxia-driven treatment failure (Ming L. Int J Cancer 
2013;132:1323-1332). Combination with AQ4N, a unidirectional 
hypoxia activated pro-drug (uHAP), blocked this progression. We 
have now characterised gene expression changes during treatment 
and have investigated the effect of a novel uHAP (OCT1002) in 
blocking these effects. LNCaP prostospheres were treated with 
vehicle, BCA, OCT1002 and combination therapy. Prostosphere 
size was measured pre and post treatment. Clonogenic assays 
and flow cytometry was carried out on treated prostospheres to 
measure changes in invasive potential and apoptosis, respectively. 
Furthermore, LNCaP-Luciferase expressing cells (4x106) were 
implanted into SCID mice, treatment (as above) commenced when 
tumours reached ~150mm3. Tumours were measured every 2 days 
using calipers.  Bioluminescence in the lung was calculated at the 
experimental endpoint. In vitro and in vivo data reveal the potential 
of OCT1002 when used in combination with BCA. Combination 
treated prostospheres had stunned growth rate, higher apoptosis 
and reduced colony formation compared to control groups.  In vivo 
data shows that combination therapy results in a significant tumour 
growth delay and reduced lung metastases by approximately 40%.
P20.  Schizophrenia-associated SNPs proximal to 
neurotransmission genes impact cognitive performance in 
patients and controls
D Cosgrove1, D Morris1,2, D Harold2, M Gill2, A Corvin2, G 
Donohoe1,2
1The Cognitive Genetics & Cognitive Therapy (CogGene) Group, 
School of Psychology and Discipline of Biochemistry, National 
University of Ireland, Galway, 2Neuropsychiatric Genetics 
Research Group, Department of Psychiatry, Institute of Molecular 
Medicine, Trinity College Dublin, Ireland
Schizophrenia (SZ) is characterised by positive, negative and 
cognitive symptoms. As SZ is highly heritable, recent research 
has focused on GWAS, the most recent of which identified 83 new 
regions of interest associated with SZ. The link between these and 
specific functions in SZ is currently unknown. To take these results 
forward, these need to be identified, be that at the level of protein, 
neural pathway or phenotype.
To characterise the effect of SNPs on cognitive function, first a 
selection was carried out based on the following classifications 1: 
proximity of SNP to gene, 2: unique association of this gene to SNP, 
and 3: gene involvement in neurotransmission, which is disrupted 
in SZ. This resulted in a selection of eleven SNPs in close proximity 
to ten genes: four involved in glutamatergic neurotransmission 
(GRM3, GRIN2A, SRR, CLCN3), five signalling (CACNA1C, 
CACNB2, HCN1, RIMS1) and two receptor genes (DRD2, CHRN). 
Neuropsychological measures of social cognition (Reading the 
Mind in the Eyes, Hinting Task, Internal, Personal, Situational and 
Attributional Questionnaire) were analysed to assess the impact of 
each SNP on social cognitive function. 
Analyses indicated a significant effect on measures of cognition in 
patients and controls. SNPs in the regions of CACNB2 (r2=0.032, 
p=0.001) and RIMS1 (r2=0.007, p=0.032) show a significant 
effect on scores on the Hinting Task and Reading the Mind in the 
Eyes, respectively. These findings implicate risk SNP effects on 
the generalised neurotransmission process as opposed to any one 
specific neurotransmitter.
P21.  Impaired cognition in schizophrenia: Genetic risk factors 
related to MHC loci
J Holland1, D Morris2, D Cosgrove3, D  Harold4, O Mothershill5, A 
Corvin6, G Donohoe
1NiCog Research group for genetics and Neuroimaging, 
Departments of Psychology and Biochemistry, National University 
of Ireland, Galway, 2Neuropsychiatric Genetics research group, 
Department of Psychiatry, Institute of Molecular Medicine, Trinity 
College Dublin
Introduction: Although the etiology of schizophrenia (SZ) is largely 
unknown, it is increasingly clear that genetic and environmental 
interactions contribute to cognitive deficits associated with this 
disorder. Recent Genome wide association studies (GWAS) have 
indicated a link between SZ and immune dysregulation, especially 
genetic mutations related to the major histocompatibility complex 
(MHC). Cognitive deficits are core features of Schizophrenia and 
related disorders, which relate to genetic risk. This study aims to 
explore the relationship between MHC risk variants for SZ and 
cognitive deficits, while also relating findings to brain activity.
Methods: To test if MHC risk variants impair cognition, ANCOVA 
analysis is performed on genetics data previously collected in a 
GWAS. Cognition measures are compared in groups with and 
without MHC genetic risk, in a population of SZ sufferers and 
healthy controls. Functional MRI imaging will also be performed 
to test if genetic risk relates to altered neural activity.
Results: Preliminary analyses suggest that MHC risk variants 
contribute to impairments in cognition in domains of social 
cognition, IQ and attention. Further analysis will be performed to 
test for environmental mediators of this relationship, looking at 
cannabis use and urbanicity. BOLD fMRI will also be used to test 
for a relationship between MHC risk and altered neural activity, 
using MATLAB SPM.
Conclusions: The MHC genetic variant may serve as a significant 
risk marker for schizophrenia, and further elucidate etiology of 
this neurodevelopmental disorder. Future studies on neurobiology 
of social cognition, and greater knowledge of genetic risk may 
establish targets for interventions.
P22.  In vivo gene silencing by siRNA delivery to the corneal 
epithelium in a keratin-12- bioluminescence mouse model
SD Atkinson1, EH Allen2,3, JE Moore4, DG Courtney2, E Maurizi2, 
MA Nesbit2, WHI McLean3, DM Leslie Pedrioli3, CBT Moore2
1Northern Ireland Centre for Stratified Medicine, CTRIC, 
Altnagelvin Hospital Site, Derry/L’Derry, BT47 6SB, 2School of 
Biomedical Sciences, University of Ulster, Coleraine, BT52 1SA, 
3Dermatology and Genetic Medicine, Colleges of Life Sciences and 
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Medicine, Dentistry & Nursing, University of Dundee, Dundee, 
DD1 5EH, 4Cathedral Eye Clinic, Belfast, BT15 1ED.
Aim: To create a bioluminescence mouse model which expresses 
firefly luciferase in the corneal epithelium to assess gene editing 
and gene silencing for the cornea.
Methods: A gene targeting vector was generated where the Krt12 
coding sequence in and the splice donor site of exon 1 were 
replaced with a transgene cassette containing a luc2-Multiple 
Targeting Cassette (MTC) gene fusion. The vector was transfected 
by electroporation into the Taconic Artemis C57BL/6N Tac ES cell 
line.  Homologous recombinant clones were isolated and validated, 
and the mice bred with luc2-positive/ PuroR-negative offspring 
used for colony establishment.
To visualise the expression of luc2 within the corneal epithelium, 
luciferin substrate diluted in viscotears was applied to the front of 
the eye and then luciferase expression was imaged and assessed 
using a Xenogen IVIS Lumina Imager and LivingImage 3.2 
software.  
Intrastromal injection of siGlo siRNA was used to determine the 
localisation of siRNA within the corneal epithelium and then the 
established mouse model was treated with either native or Accell 
“self-delivery” siRNA.
Results: The Accell “self-delivery” siRNA induced potent sustained 
allele specific silencing for 7 days, while native versions of siRNA 
resulted in significant knock-down for 1 day only (p<0.05).
We have created and validated a bioluminescence mouse model and 
have utilised it to assess siRNA in vivo. This mouse model coupled 
with the Lumina imager will allow us to assess topical delivery of 
gene therapies to the ocular surface allowing validation for future 
translation to clinical use.
P23.  Mutant allele-specific gene silencing in autosomal 
dominantly inherited Fuchs’ corneal dystrophy using CRISPR 
Cas9 nuclease
E Maurizi1, D Courtney1, SD Atkinson1, JE Moore1, MA Nesbit1, 
CBT Moore1
1Dept of Biomedical Sciences, Ulster University, Coleraine UK
Dominant-negative or gain-of-function disease-causing mutations 
are not suitable for gene supplementation therapies. The CRISPR 
Cas9 system has emerged as a powerful in vivo and in vitro 
RNA-guided sequence specific nuclease. Critical for target site 
recognition by the Cas9 nuclease, a 3bp protospacer-adjacent 
motif (PAM) is located adjacent to its 3’end. A review of known 
point mutations that cause corneal dystrophy showed that over 
30% result in the formation of a novel PAM site. To investigate 
whether these mutations could be specifically targeted by CRISPR/
Cas9 we focused our attention on the Fuchs’ endothelial corneal 
dystrophy (FECD), where the L450W mutation in the alpha2 chain 
of Collagen VIII (COL8A2) gene creates a new PAM site absent in 
the wild-type allele.
In vitro assays were designed to determine the efficiency and 
specificity of Cas9 cleavage. Wild-type and mutant COL8A2 genes, 
cloned into a Luciferase reporter vector, together with single guide 
RNA (sgRNA) Cas9 constructs, were used to transfect AD293 
cells. The sgRNA targeting Cas9 to a site adjacent to the L450W 
mutation showed a significant (50% ± 3.9%, p<0.01) knockdown of 
mutant allele expression, without effect on wild type.
AD293 cells were co-transfected with equimolar quantities of 
wild-type and mutant COL8A2 constructs and sgRNA/Cas9 
constructs and allele specificity was confirmed at the mRNA level 
by pyrosequencing and qPCR.
Thus, the L450W PAM-specific sgRNA was revealed to be an 
efficient genome editing tool, with the potential for developing a 
targeted therapy for FECD that will be applicable to other diseases 
caused by dominant-negative or gain-of-function mutations.
P24.  Genetic insights into the population structure of the 
Sherpa and neighbouring Nepalese populations
A Cole1, S Cox2, C Jeong3, Y Droma4, M Hanaoka4, M Ota5, P 
Gasparini6, H Montgomery2, A Di Rienzo3, P Robbins7, G L. 
Cavalleri1
1Department of Molecular and Cellular Therapeutics, The Royal 
College of Surgeons in Ireland, 2Institute for Human Health and 
Performance, University College London, 3Department of Human 
Genetics, University of Chicago, 4First Department of Medicine, 
Shinshu University School of Medicine, Matsumoto, Japan, 
5Department of Legal Medicine, Shinshu University School 
of Medicine, Matsumoto, Japan, 6University of Triests, Italy, 
7Department of Physiology, Anatomy and Genetics, University of 
Oxford.
Nepal, located on the southern-slope of the Himalayan arc, has a 
complex demographic history and is home to 125 recognised ethnic 
groups. The Sherpa, who reside in the mountainous eastern region 
of Nepal, are believed to have migrated from Tibet 400-600 years 
ago. We set out to shed light on the population structure of eastern 
Nepal, in particular the Sherpa.
We established a cohort of 118 Sherpa from multiple high-altitude 
villages in the Khumbu region of eastern Nepal. We identified seven 
ethnic groups of interest from the Nepalese census that represent 
approximately 50 % of the total Nepalese population; Chettri, 
Rai, Magar, Tamang, Newar, Nepali and Aryan. We included 82 
individuals from these ethnic groups, who were resident in regions 
in close proximity to the Sherpa.
We also included genotype-data to represent the greater Himalayan 
region which included individuals from the Pamir mountain-range, 
India, Pakistan and China. Via the analysis of dense genotype 
data, we investigated genetic distance, admixture and levels of 
homozygosity within and between populations. 
Our results suggest the Nepalese are highly-admixed population 
with ancestry primarily from north of the Himalaya but with some 
geneflow from the south. We confirmed the presence of an ancestral 
component that appears specific to high-altitude populations of the 
Himalaya. This is enriched in the Sherpa, particularly in individuals 
from the Thame village in Khumbu. Patterns of homozygosity 
observed in the Sherpa and Nepalese are consistent with 
consanguinity and are likely to be a result of population isolation.
P25.  The development and testing of a custom gene panel to 
aid clinical diagnosis in an adult epilepsy clinic
M McCormack1, S Heavin1, P Buckley1, N Delanty2, GL Cavalleri1
1Molecular and Cellular Therapeutics, Royal College of Surgeons 
in Ireland, 2Department of Neurology, Beaumont Hospital Dublin.
Around 40,000 people in Ireland are living with epilepsy and 
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approximately 30% of patients are refractory to treatment. A 
clear understanding of the underlying cause offers the potential to 
improve treatment for refractory epilepsy. Further, a fast, accurate 
diagnosis reduces the diagnostic odyssey and associated expensive 
testing.
Next-generation sequencing can give complete ascertainment of 
genetic variation across the genome, or focused ascertainment within 
the coding regions of a subset of genes. This enables clinicians to 
identify known pathogenic mutations or novel candidate mutations 
that may cause a patient’s epilepsy. Recent studies have illustrated 
the relatively high diagnostic yields for gene-panel and exome 
sequencing in epileptic encephalopathies, with yields in the region 
of 20-30%. In this study we set out to develop a gene panel for 
epilepsy, and test the diagnostic yield in a refractory, adult patient 
cohort.
We used Agilent SureDesign to design a custom gene panel 
containing over 400 genes linked to epilepsy and epileptic 
encephalopathies from published literature and a review of similar 
commercially available panels. We selected for sequencing a 
subgroup of patients (n=30) with a suspected genetic cause to their 
epilepsy. DNA samples were be enriched using the SureSelect QXT 
protocol before sequencing on an Illumina MiSeq. Alignment and 
variant calling was performed using Burrows-Wheel Aligner and 
SureCall software. We utilized databases such as OMIM, ClinVar 
and available literature to arrive at a set of candidate variants.
Results from this study will inform on the effective integration of 
next-generation sequencing to adult epilepsy clinics in Ireland.
P26.  5-Hydroxymethylation marks a class of neuronal gene 
regulated by intragenic methylcytosine levels
RE Irwin1, A Thakur1, KM O’ Neill1, CP Walsh1
1Dept. of Transcriptional Regulation and Epigenetics, Ulster 
University
We recently identified a class of neuronal gene inheriting high 
levels of intragenic methylation from the mother and maintaining 
this through later development. We show here that these genes 
are implicated in basic neuronal functions such as post-synaptic 
signalling, rather than neuronal development and inherit high levels 
of 5mC, but not 5hmC, from the mother. 5mC is distributed across the 
gene body and appears to facilitate transcription, as transcription is 
reduced in DNA methyltransferase I (Dnmt1) knockout embryonic 
stem cells as well as in fibroblasts treated with a methyltransferase 
inhibitor. However in adult brain, transcription is more closely 
associated with a gain in 5hmC, which occurs without a measurable 
loss of 5mC. These findings add to growing evidence that there may 
be a role for 5mC in promoting transcription as well as its classical 
role in gene silencing. Further interrogation of the mechanisms 
behind the persistence of gametic marks could potentially lead to 
insights into neurological disorders.
P27.  The MTHFR A667C polymorphism and its association 
with reduced fertility
Paul Cummins1
1Sims IVF clinic, Clonskeagh Road, Clonskeagh , Dublin 14, 
Ireland. 
The MTHFR gene located at 1p36.3, encodes the folate dependent 
enzyme 5,10-methylenetetrahydrofolate reductase, necessary 
for homocysteine metabolism and paramount in the creation of 
active vitamin B9. Defects in the gene have been associated with 
a plethora of pathological states such asCVD, congenital defects, 
reduced pregnancy and cancer. 
The C677T polymorphism has been associated with various 
anencephalies, chiefly neural tube defects. During embryology 
NTD’s are a known risk factor for late stage spontaneous abortion 
leading to reduced fertility. To assess the risk of MTHFR derived 
infertility we assessed 466 women attending a fertility clinic for the 
MTHFR polymorphism using ARMS PCR. 
We found 248 (61%) of patients carried the C677T polymorphism 
while 181 (39%) did not carry the mutation. Of the 248 which 
were found to carry the polymorphism 203 were heterozygous for 
the mutation while 45 were homozygous. This data highlights the 
necessity for MTHF genetic testing. As described above, variations 
in the MTHFR gene may increase the risk of neural tube defects 
by changing the ability of methylenetetrahydrofolate reductase to 
process folate. Once MTHFR status is known doctors can then 
supplement folate more reliably. 
P28.  Differential responses of clinically important gene classes 
to transient loss of DNA methylation in human differentiated 
cells
SJ Mackin, K O’Neill, C Walsh
Transcriptional Regulation and Epigenetics Research Group, Ulster 
University, Coleraine.
Background: Methylation of DNA sequences at promoters, CpG 
islands and other elements plays a vital role in regulating gene 
activity. In human, loss of methylation is known to play a causative 
role in imprinting disorders and in inappropriate germline gene 
expression in cancers. While in mouse, loss of function mutants have 
given great insight into the targets of methylation, functional studies 
in human have been largely limited to cancer cells and more recently 
stem cells, not normal adult cells. Methods: Stable knockdowns 
of the maintenance methyltransferase DNMT1 were generated in 
normosomic hTERT-immortalised adult fibroblasts. Genome-wide 
methylation levels were assayed using the Illumina 450K bead 
array. Results were analysed using RnBeads and Galaxy. Locus-
specific methylation was verified using pyrosequencing and clonal 
analysis. Validation was achieved using transient siRNA. Results: 
Loss of function was poorly tolerated and all clonally-expanded 
cell lines had spontaneously restored DNMT1 levels by silencing 
of the shRNA. Evidence for a genome-wide methylation erasure 
event followed by a wave of remethylation could be clearly traced. 
Gene bodies and the shores of CpG islands showed the clearest 
loss of methylation overall. While most CpG islands are normally 
unmethylated and so unaffected, both imprints and germline genes 
fall into the rarer category of normally methylated islands: of 
these two, lasting loss of methylation was much more common 
among imprints than germline genes. Conclusions: 1: transient 
loss of methylation is poorly tolerated; 2: a robust mechanism for 
remethylation exists even in adult cells; 3: aberrant remethylation 
is frequent on recovery and 4: Imprints are particularly sensitive.
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P29. Whole exome sequence analysis in a multigeneration 
Northern Irish family with pterygium
E Maurizi1, D Schiroli1, MA Nesbit1, JE Moore1,2, SD Atkinson1, 
and CBT Moore1
1School of Biomedical Sciences, University of Ulster, Coleraine, 
BT52 1SA, Northern Ireland,  2Cathedral Eye Clinic, Belfast, BT15 
1ED, Northern Ireland
Pterygium is a wing-shaped fibrovascular lesion of the ocular 
surface that leads to blindness in  severe cases; it is reported as 
a premalignant condition with the potential to progress to ocular 
surface squamous neoplasia. Epidemiological studies show a 
correlation between pterygium and prolonged and intense exposure 
to ultraviolet (UV) light. In certain families however a much higher 
susceptibility to development of pterygium has been observed, 
suggesting a genetic cause.
Whole exome sequencing (WES) was performed to determine a 
causative mutation in five affected individuals and one unaffected 
sibling from a Northern Irish family (6 affected and 18 unaffected) 
with pterygium in multiple generations, in whom UV-B exposure 
was documented to be much lower than at equatorial latitudes.
Variant alleles identified by WES were screened with an assumption 
of autosomal dominant inheritance. The number of candidates genes 
were reduced, using different filters (confidence, common variants, 
predicted deleterious and genetic screening), to five, and then to 
one biologically plausible candidate through literature analysis. 
Cosegregation of the variant allele with pterygium in the family 
was confirmed by PCR and restriction enzyme analysis.
Expression of this gene in pterygium tissue samples, from both low 
UV-exposure (Northern European) and high UV-exposure (South 
American) populations was assessed. In vitro functional MTT 
and scratch assays demonstrated increased proliferation in cells 
transfected with the mutant compared to wild-type gene.
This study shed lights on the possible genetic mechanisms 
underlying pterygium formation, suggesting a role for the identified 
candidate gene in the general mechanism of UV-induced pterygium.
P30.  Investigating the role of polymorphism rs2910164 in 
mir146a in cancer predisposition
TP McVeigh1,2, P Owens2, R Mulligan2, N Miller2, F Sebag3, D 
Quill4, M Bell4, AJ Lowery2,4, JB Weidhaas5, MJ Kerin2,4
1Department of Clinical Genetics, Our Lady’s Children’s Hospital, 
Crumlin,  2Discipline of Surgery, National University of Ireland 
Galway, 3Department of Endocrine Surgery, Hospital de la 
Timone, Marseilles, France, 4Galway University Hospital, Ireland, 
5University of California, Los Angeles, USA
Micro(mi)RNAs are non-coding RNA molecules that bind with 
cis-regulatory regions in target messenger(m)RNA to exert post-
transcriptional effects on gene expression, influencing a host of 
physiological and pathological processes. Polymorphisms in genes 
encoding miRNAs, or in miRNA-mRNA binding sites have been 
associated with cancer risk. MiR146a has a role in inflammation 
and is postulated to be a tumor suppressor miRNA.
The aim of this study was to investigate the frequency and impact of 
polymorphism rs2910164 in HSA-pre-mir146a in a cohort of patients 
with breast and thyroid cancer compared to cancer free controls.
The study group comprised Irish patients with breast cancer and 
French and Irish patients with non-medullary differentiated thyroid 
cancer (DTC), as well as cancer free controls. DNA from study 
participants was genotyped using a Taqman-based platform. Data 
was analysed using SPSS v22 and the Online Encyclopedia for 
Genetic Epidemiology studies.
The study group included 1250 patients, including 637 controls, 
524 breast and 179 DTC cases. The variant was detected with a 
minor allele frequency (MAF) of 0.18 in controls, 0.21 in breast, 
and 0.28 in DTC cases. The variant conferred per allele odds ratio 
of 1.22(1-1.5, p=0.05, X2) for breast, and 1.7 (1.31-2.25, p<0.0001) 
for DTC. An allele dosage effect was observed for both cancers, 
with rare homozygous genotype conferring greater risk than 
heterozygous for both cancer types.
A common variant in pre-mir146a is associated with breast and 
thyroid cancer predisposition. Further work is required to fully 
elucidate how this finding can be made clinically useful.
P31. The Dihydrofolate reductase 19bp polymorphism is not 
associated with biomarkers of folate status in healthy young 
adults, irrespective of folic acid intake
M Ozaki1, AM Molloy2, JL Mills3, R Fan3, Y Wang3, ER Gibney4, B 
Shane5, LC Brody6, A Parle-McDermott1
1Nutritional Genomics Group, School of Biotechnology, Dublin 
City University, Glasnevin, Dublin 9, Ireland,  2Department of 
Clinical Medicine, School of Medicine, Trinity College Dublin, 
Dublin 2, Ireland, 3Division of Intramural Population Health 
Research, Eunice Kennedy Shriver National Institute of Child 
Health and Human Development, NIH, Bethesda, MD, 4Institute 
of Food and Health, University College Dublin, Dublin 4, Ireland, 
5Genome Technology Branch, National Human Genome Research 
Institute (LCB), NIH, Bethesda, MD
6University of California, Berkeley, CA.
Background: Dihydrofolate reductase (DHFR) is essential for the 
conversion of folic acid to active folate needed for one-carbon 
metabolism. Common genetic variation within DHFR is restricted 
to the noncoding regions and previous studies have focused on a 
19 bp deletion/insertion polymorphism (rs70991108) within intron 
1.  Reports of an association between this polymorphism and blood 
folate biomarker concentrations are conflicting. 
Objective: We aimed to evaluate whether the DHFR 19bp deletion/
insertion polymorphism affects circulating folate biomarkers in the 
largest cohort to address this question to date. 
Methods: Young healthy Irish individuals (n= 2,507) between 19 
to 36 years old were recruited between February 2003 and 2004. 
Folic acid intake from supplements and fortified foods was assessed 
using a customized food intake questionnaire.  Concentrations of 
serum folate and vitamin B-12, red blood cell (RBC) folate and 
plasma total homocysteine (tHcy) concentration were measured. 
Data were analysed using linear regression models.  
Results: Folic acid intake was positively associated with serum 
(P <0.0001) and RBC folate concentration (P = 0.0005) and was 
inversely associated with plasma tHcy (P = 0.001) as expected. The 
DHFR 19 bp polymorphism was not significantly associated with 
either serum (P = 0.82) or RBC folate (P = 0.21), or plasma tHcy 
(P = 0.20), even in those within the highest quintile of folic acid 
intake (>326µg folic acid/day; P = 0.96).  A non-significant trend 
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towards lower RBC folate by genotype (P = 0.09) was observed in 
the lowest folic acid intake quintile (0 – 51 µg/day). 
Conclusion: In this cohort of young healthy individuals the DHFR 
19bp deletion allele does not significantly affect circulating 
folate status, irrespective of folic acid intake.  Our data rule out 
a strong functional effect of this polymorphism on blood folate 
concentrations. 
P32.  Mapping Human Ancestry On The New York Subway 
System
ET O’Halloran, A Ebrahim, C Meydan, C Mason, TR Magalhães, 
S Ennis
ACoRD, School of Medicine and Medical Science, University 
College Dublin
In recent years the concept of analysing large amounts of data 
as part of the development of ‘Smart Cities’ has emerged. In the 
Pathomap project, led by Dr. Christopher Mason from Weill Cornell 
Medical College and with UCD ACoRD participation, DNA was 
sequenced from thousands of samples taken from surfaces in the 
New York City Subway System. The purpose being to catalogue the 
microbiome of the subway for the first time and monitor changes to 
better understand the spread of pathogens.
Human DNA was also sequenced; using the ancestry analysis 
software AncestryMapper and Admixture, we examined how the 
genetic profile of stations matched that of the ethnic and racial 
demographics of the area as per the 2010 census.
Hispanic and African American populations being highly admixed 
presented interesting challenges. Since the samples were derived 
from multiple individuals, the results presented many interpretations; 
for example, did the result indicate an area that was 20% black and 
80% white or 100% Puerto Rican. Should one assume an average of 
~14% European ancestry for African Americans? Is that nationally-
average number appropriate for New York? We found areas with 
high levels of consistency, particularly ones with homogeneous 
populations and others where the method did not seem to match the 
area, few were completely against the local demographics.
In the course of this we built an automated pipeline to work through 
the hundreds of samples, uploading this to Curoverse, a web 
infrastruture that hosts open-source bioinformatic and genomic 
software as part of the Arvados project.
